. ~~~~~t'~~,fP~~~li,g~~~~t . . In view of the importance of Candida drug resistance protein (CdrIp) in azole resistance, we have characterized it by overexpressing it as a green fluorescent protein (GFP)-tagged fusion protein (Cdrlp-GFP). The overexpressed Cdrlp-GFP in Saccharomyces cerevisiae is shown to be specifically labeled with the photoaflinity analogs iodoarylazidoprazosin (IAAP) and azidopine, which have been used to characterize the drug-binding . sites on mammalian drug-transporting P-glycoproteins. While nystatin could compete for the binding ofIAAP, miconazole specifically competed for azidopine binding, suggesting_that IAAP and azidopine...bind to separate. sites on Cdrlp. Cdrlp was subjected to site-directed mutational analysis. Among many mutant variants of Cdrlp, the phenotypes of F774A and 1l.F774 were pa. rticularly interesting. The analysis of GFP-tagged mutant variants of Cdrlp revealed that a conserved F774, in predicted transmembrane segment 6, when changed to alanine showed increased binding of both photoaffinity analogues, while its deletion (1l.F774), as revealed by confocal microscopic analyses, led to mislocalization of the protein. The misiocalized 1l.F774 mutant Cdrlp could be rescued to the plasma membrane as a functional transporter by growth in the presence of a Cdrlp substrate, cycloheximide. Our data for the first time show that the drug substrate-binding sites of Cdrlp exhibit striking similarities with those of mammalian drug-transporting P-glycoproteins and despite differences in topological organization, the transmembrane segment 6 in Cdrlp is also a major contributor to drug substrate-binding site(s).
Candida albicans is an opportunistic diploid fungus that causes infections in immunocompromised and debilitated patients (34) . Widespread and prolonged usage of azoles in recent years has led to the rapid development of the phenomenon of multidrug resistance (MDR), which . poses a major hurdle in antifungal therapy. Various mechanisms which contribute towards the development of MDR have been implicated in Candida, and some of these include overexpression of or mutations in the target enzyme of azoles, lanosterol 14ademethylase, and overexpression of drug efflux pumps (I, 33) belonging to the ATP-binding cassette (ABC) transporter channel superfamily (18) and to the major facilitator superfamily of transporters (MFS) (22, 35) . Among ABC transporters, CDR1 has been shown to playa key role in azole resistance in C. albicans as deduced from its high level of expression found in several azole resistance clinical isolates recovered from patients receiving long-term antifungal therapy (41, 39) . Additionally, high-level expression of CDR1 invariably contributes to an increased efflux of fluconazole, thus corroborating its direct involvement in drug efflux (24, 38) . Cdrlp has not onJy acquired significant clinical importance but is considered an important player in any design of strategies to combat antifungal resistance.
The CDR1 gene encodes an integral plasma membrane (PM) protein of 1,501 amino acids, with a predicted molecular mass of 169.9 kDa. On the basis of its amino acid sequence, Cdrlp is predicted t o consist of two homologous halves, each comprising one NJerminal hydrophilic domain followed by a C-terminal hydrophobic domain. The hydrophilic domain comprised a consetved ABC region, including the ATP-binding motifs known as the Walker A and Walker B motifs (48) and another highly consetved !Dotif, ABC signature, preceding the Walker B motif (36) . Cdrlp has a similar topology to its close homologues Pdr5p and Snq2p of Saccharomyces cerevisiae (36) .
According to our current understanding, Cdrlp and Cdr2p drug extrusion proteins not only efflux azoles and its derivatives but also extrUde a variety of structurally unrelated drugs. Overexpression of homologous ABC multidrug transporter proteins, human P-glycoprotein (P-gp) or the MDR-associated protein 1 (MRP1) is also responsible for the molecular basis of the MDR phenotype in tumor cells (3) . The molecular mechanisms which govern Cdrlp functions are not well-known, and information is needed (i) to understand how the protein can bind a structurally diverse range of compounds, (ii) to define drug substrate binding, and (iii) to determine how ATP binding and hydrolysis are linked to drug transport.
In an effort to develop an understanding of the molecular details of drug binding and the importance of domains in Cdrlp, in this study we have overexpressed Cdrlp as a green fluorescent protein (GFP)-tagged fusion protein (Cdrlp-GFP) Srrain ADl-8u-ADl-8u- Reference Decottignies et al. (9) This study This study Nakamura et al. t33j Nakamura et al. (33) This study
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This study in a heterologous system and for the first time characterized it for drug and nucleotide binding. The GFP-tagged Cdrlp was functionally similar to its untagged version, as it imparted drug resistance to S. cerevisiae cells, showed ATPase activity, and efHuxed Cdrlp substrates, such as rhodamine 6G. Photoaffinity P-gp substrate analogues were used to assess the drug substrate sites of Cdrlp. For this, we used iodoarylazidoprazosin (IAAP, a photoaffinity analogue of the P-gp substrate, prazosin) and azidopine (a dihydropyridine photoaffinity analogue), which are known to bind specifically to the human and murine drug transporting P-gps. Our study demonstrates that both IAAP and azidopine bind specifically to Cdrlp-GFP. Interestingly, lAAP binding was competed out by nystatin, while azidopine binding could only be competed out by miconazole, thus demonstrating the possibility of different drug-binding sites for the two analogues.
It appears that F774 in TMS6 is important for the localization of Cdrlp.
MATERIALS AND METHODS
Materials. Anti-GFP Tflonoclonal antibody was purchased from BD Bier sciences Oontech, Palo Alto, Calif. DNA-modifying enzymes were purchased from Roche Molecular Biochemicals. Protease inhibitors, miconazole, nystatin, cycloheximide, anisomycin, rhodamine 6G, and other molecular grade chemicals were obtained from Sigma Chemical Co. ( (Table I) . PSCDRI-GFP, SS5G (F774A), and SS6G (A.F774) were ADI·8u-derivatives expressing Cdrlp-GFP and its mutant proteins (mutant Cdr! p-GFPs) ( Table I) . The yeast strains were cultured in yeast extract-peptone-dextrose (YEPD) broth (Bio 101, Vista, Calif.) or SD-URA medium (Bio tOI). For agar plates, 2% (WI/vO!) Bacto agar (Difco, BD Biosciences) was added to the medium .
For functional analysis, mutations were introduced in predicted nucleotide-binding domain 1 (NBDl), transmembrane segment 6 (TMS6), NBD2, cytoplasmic loop 5 (CLS), and extracellular loop 6 (EL6). On the basis of phenotypic analysis, two mutants in TMS6 (F774A and llF774) were subjected to detailed analysis by overexpressing them as GFP-tagged proteins. Of note, the substitution of F774 with A in TMS6 resulted in a selective loss of unctional activity of the mutated protein, while a deletion of the same phenylalanine (llF774) led to improper localization of the mutant protein. OUf results further show that if mutant cells in which F774 had been deleted were grown in the presence of cycloheximide, it led to the appearance of a functional transporter at the cell surface.
Generation of polyclonaJ antibody to Cdrlp. The peptide CQSNKISKKEK DDYVDY (amino acids %5 to 979, part of the putative NBD2), which repre· sented the predicted most antigenic epitope of Cdr I p, wa~ commercially synthe· sized and conjugated to keyhole limpet hemocyanin by Princeton Biomolecules. The antisera were raised in a New Zealand White rabbit after injecting 250 ",g of conjugated peptide and giving a booster dose after 2 months. The antiserum was collected after 2 months (uulle by Covanee Research Products, Inc.) and used at a dilution of 1:500 for Western blot analysis.
Molecular doning. A GFP tag was attached at the C-terminal end of CDR/. The GFP open reading frame (ORF) was amplified from plasmid pGFP31 (31) (a kind gift from Joachim Morschhauser, Zentrum fUr Infectionsforschung, Uni· versitat Wiirzburg, Wiirzburg, Germany) using the following primers. The for· ward primer was 5'·ACGCGTCGACATGAGTAAGGGAGAAGAA-3' (the San site is shown in hold type), and the reverse primer was 5'-ACGCGTCGAC GGACTAGTITArrrGTATAGTTCATCCA·3' (the Soil site is shown in hold type, and the Spel site is shown in hold italic type). This GFP amplicon was digested with Sail restriction enzyme. The stop codon of CDR! was replaced with a Sail site in p425·GPD·CDR I (kind gift from Martine Raymond. Institut de Recherches Cliniques de Montreal, Montreal, Quebec, Canada). It was then digested with Sal!, and the digested GFP amplicon was ligated to the C-terminal end 'lf CDR! . The resulting CDRI-GFP ORF was taken out of the vector p425·GPD·CDRIGFP by Spel restriction ellZ)'lTle and cloned in tbe vector pSK-PDR5 PPUS (33) (kind gift from R. D . Cannon) at the Spel site resulling in plasmid pPSCDRI-GFP. After every cloning, the orientation was checked by restriction enzyme digestion and sequencing using the Big Dye Terminator cycle sequencing kit (ABI) and ABI 310 DNA sequencer.
Site-specific mutagenesis and development of tnmsfonnants. Site-directed mutagenesis was performed by using the QuikChange mutagenesis system from Stratagene (La Jolla. Calif.). The mutations were introduced into plasmid pS12-35 and pPSCDRI·GFP according to the manufacturer's instructions, and the desired nucleotide sequence alterations were confirmed by DNA sequencing of the ORF. The mutated plasmid pS12·35 onhe mutated pPSCDR I-GFP after linearizing with Xbal was used to transform ADI234568 or ADI·8u-cells, respectively, for uracil prototrophy hy the lithium acetate transformation protocol (2) .
Genomic DNA extraction and Southern analysis or CDR! gene in S. cuevisille.
Plasmid or genomic DNA was isolated from S. cerevisille cells as described previously (19, 47) . Genomic DNA was digested with restriction endonuclease (£coRV, Bam HI, and Pstl; Roche B.iochemicals). Plasmid DNA (5 ",g) or di· gested genomic DNA (10 ",g) was separated on a 1% agarose , geJ and transferred to a Hybond + nylon membrane (Amersham). Membranes were hybridized with [a-3~PldATP.labeled CDR/-specific probe (ORF nucleotideS I to 280) under high-stringency conditions (40) . lmmunodetection of Cdrlp in PM-Crude membranes (CM) were prepared from S. cerevisille cells grown in YEPD to late exponential phase. The cells were broken with glass beads by vonexing the: cells four times for 30 s each time, followed by a 3()'s interval on ice. The homogenization medium contained 50 mM Tris (pH 7.5), 2.5 mM EDTA, and the protease inhibitor cocktail (I mM phenylmethylsulfonyl fluoride, I ",g of leupeptin per ml, pepstatin A, and aprotinin). The CM were recovered by centrifuging at t , 000 x g to remove unbroken cells and pelle ting the CM by ultracentrifugation at 100,000 X g for J h. The CM were resuspended in resuspension buffer (10 mM Tris (PH 7.5), 0.5 mM EDTA, 10% glycerol). The CM were applied to a discontinuous gradient made of an equal volume of 53.5 % (wt/vol) sucrose and 43.5% (WlNol) sucrose. Following centrifugation for 5 h at 100,000 x g in a Beckman SW 28 rotor, the purified PMs were recovered at the interface of the 43.5 and 53.5% sucrose layers by the method of Monk et al. (30) . The protein samples (20 ",g) were separated on sodium dodecyl sulfate (SDS}-8% polyacrylamide gels and either stained with colloidal Coomassie blue G250 or electrohlotted (40 V, I h, 4°C) onto nitrocel· lulose membranes (Invitrogen Ufe Technologies). The membranes were incu· bated with anti·Cdrlp polyclonal antibody (diluted I:SOO), anti·Pmal p poly· clonal antihody (diluted 1:10,(00), or anti·GFP monoclonal antibody (diluted 1:1,000). Immunoreactivity of Cdrlp and Pmalp antibodies was detected with horseradish peroxidase (HRP).labeled goat anti·rabbit antibody, which was diluted 1:20,000 in 20% fat-free milk. Immunoreactivity of GFP antibody was detected with an anti-mouse antibody, which was diluted I : 1 0,000 in 5% fat-free milk. Proteins on immunoblots were visualized using the enhanced chemilumi· nescence assay system (ECL kit; Amersham Biosciences).
Drug susceptibility of S. cuevisille. The susceptibilities of S. cerevisiae cells to different drugs were determined by microtiter and spot assays as described earlier (32) . ATPase assay. Cdrlp.associatcd ATPase activi ty of the purified PM was mea· sured as an oligomycin-sensitive release of inorganic phosphate. Membrane suspension (10 ",g of PM protein as determined by amido black B protein estimation) (46) was incubated at 3erC in 0.1 ml of a medium containing 59 mM Tris (pH 7.5) and 7 mM MgCl 2 (ATPase assay buffer) and 20 ",M oligomycin where indicated. To eliminate possible contributions from nonspecific phospha. tases and vacuolar and mitochondrial ATPases, 0.2 mM ammonium molybdate, Cdrlp 1363 50 mM KNO J , and 10 mM NaN J • respectively, were included in the reaction mixture. The reaction was started by the addition of 5 mM ATP and was stopped by the addition of 0.1 ml of 5% SDS solution. The amount of inorganic phosphate released was immediately determined as described previously (42) .
Rhodamine 6G ellux. The elflux of rhodamine 6G was determined essentially by a previously described protocol (29) . Approximately \0 7 cells from a culture grown overnight were inoculated in 250 ml of YEPD and grown for 5 h at 3ere. The ceUs were pelleted and washe" three times with phosphate·buffered sal ine (PBS) without glucose. The cells were subsequently resuspended as a 2% cell suspension in PBS to which rhodamine 6G was added to a final concentration of 10 ",M and incubated for 2 h at 3erC. -Ibe cells were then washed and resus· pended in PBS with 2% glucose. An aliquot of I ml was taken after 45 min and centrifuged at 9,000 x g for 2 min. The absorbance of the supernatant wa~ measured at 527 nm. Confocal microscopy. The cells were grown in SD-URA medium to late log phase. The drugs were added 4 h after the inoculation as indicated. The cells were washed and resuspended in an appropriate volume of 50 mM HEPES (PH 7.0). The cells were placed on the glass slides, and a drop of antifade reagent (Fluoroguard high-performance antifade reagent; Bio-Rad, Hen:ules, Calif.) was added to prevent photobleaching. The cells were directly viewed witb a Bio-Rad confocal microscope (MRC 1024) with a lOO x oil i mmersion objective.
Flo ... cytometry of tbe cells. Flow cytometric analysis of the Cdrlp-GFP· carrying S. cerevisiae cells was performed with a FACSort flow cytometer (Ber· ton·Dickinson Immunocytometry Systems, San Jose, Calif.). Cells were grown to mid-log phase, and 10" cells Were harvested and washed with 50 mM HEPES (pH 7.0). Cells were resuspended in 500 ",I of 50 mM HEPES (pH 7.0). Ten thousand cells were analyted in acquisition. Analysis WdS performed with CeUQuest soft· ware (Becton·Dickinson lmmunocytometry Systems). The mean fluorescence intensity was calculated using the histogram stat program. Pbotodioity labeling with lAAP_ The PM proteins (15 ",g) were incubated with the indicated competing drug for 10 min at 37"C in 50 mM Tris·HO (PH 7.5). -Ibe samples were brought to room temperature, and 3 to 6 nM [llSIJIAAP (2, 200 Ci/romol) was added and incubated for an additional 5 min under subdued light The samples were then illuminated with a UV lamp assembly (PGC Scientifies, Gaithersburg. Md.) fitted with two black light (self-filtering) UV-A long·wavelength EJ518BLB rubes (365-nm wavelength) for 10 min at room temperature (21 to 23°C). Following SDS·polyacrylamide gel electrophoresis (SDS-PAGE) on an S% Tris-glycine gel at constant voltage, gels were dried and exposed to Bio-Max MR film (Eastman Kodak, Rochester, N.Y.) at -SO"C for 12 to 24 h. The radioactivity incorporated into the Cdrlp band was quantified using the STORM 860 Phosphor Imager system (Molecular Dynamics, Sunnyvale, Calif.) and the software ImageQuaNT as described previously (44) .
Pbotoalinity labeling with ['Efjazidopine. The PM proteins (30 p.g) were incubated with the indicated competing drug for 10 min at 37"C in 50 mM Tris-HO (PH 7.5). The sami>les were brought to room temperature and treated with 0.5 t-o-M fH)azidopine (60 C.i/mmol) for 5 min and then photo-cross-linked at 365 nm at room temperature (21 to 23°C) for 10 min, and 5x SDS sample buffer was added . Following el. ectrophoresis, the gel was incubated with Fluro-Hance (Research Products Inc.) for 30 to 45 min and dried under vacuum, and the dried gel was exposed to an X-ray film for 3 to 6 days at -sere. The radioactivity incorporated into the Cdrlp band was quantified as described ahove.
Binding or [a-l2 PI8-azido-ATP. The PM protein (15 ",g) was incubated in the ATPase assay buffer containing 10 ",M [a-J2 P)S-azido.ATP (to ",Cilnmol) in the dark at 4"<: for 5 min in the presence or absence of 10 mM ATP. The samples were then illuminated with a UV lamp assembly (365-nm wavelength) for to min on ice (4°C) as described previously (45) . Following 5DS-PAGE on an S% Tris-glycine gel at constant voltage, the gels were dried and exposed to Bio-Max MR film at -serc for 12 to 24 h. The radioactivity incorporated into the Cdrlp band was quantified as described ahove.
RESULTS
The Candida drug resistance protein (Cdr1p), a member of the ABC superfamily, causes MDR by an active efflux mechanism, which keeps the intracellular level of antimycotic compounds, such as azoles, below a cell-killing threshold. Similar to other well-characterized multi drug ABC transporters, Cdrlp (-170 kDa) comprises two NBDs and 12 TMSs. NBDs are the hub of A TP hydrolysis activity and are considered critical for ABC protein-mediated drug efflux. In an attempt to functionally characterize the Cdrlp in terms of drug and nucleotide binding and the importance of domains in drug interactions, in this study we have overexpressed Cdrlp as a GFPtagged protein. The functional characterization of wild-type Cdrlp-GFP and of the mutant variants generated by site-directed mutagenesis are the subject of the following experiments.
Overexpressed Cdrlp-GFP is fully functional. In order to confirm the PM localization of Cdrlp and for biochemical characterization, we used an expression system developed by Nakamura et al. (33) , which was a generous gift from R. D. Cannon, where CdrIp was stably overexpressed from a genomicPDR5 locus in an S. cerevisiae mutant, ADI-8u-. The ADl-8u-mutant was derived from apdrl-3 mutant strain with a gain-of-function mutation in the transcription factor Pdrlp, resulting in a constitutive hyperinduction of the PDR5 promoter. The high-level expression of Cdrlp was obtained by integration of the CDRl ORF to the PDR5 promoter in ADl-8u -, and the resulting strain was designated AD1002 (33) . We tagged the GFP gene at the C-terminal end of CDR1, which was overexpressed as a fusion protein in the PSCDRI-GFP strain ( Fig. la) . A single-copy integration of GFP-tagged CDR1 was ensured by Southern hybridization of restricted genomic DNA with a CDRl-specific probe as described earlier (33) (data not shown).
The presence of larger amounts of Cdrlp and Cdrlp-GFP in the purified PM fractions of AD I 002 and PSCDRI-GFP cells could be detected on an SDS-polyacrylamide gel when stained by Coomassie brilliant blue G250 dye ( Fig. Ib) , which was ' further confirmed by Western blot analysis of the PM proteins using Cdrlp polyclonal antibody. Figure lc confirms that the Cdrlp and Cdrlp-GFP were expressed in PM fractions to the same levels. There was an expected -30-kDa difference in the observed molecular mass of Cdrlp-GFP compared to that of . CJrlp because of the GFP tag attached to the C-terminal end of Cdrlp (Fig. Ic) . The Pmal antibodies were used as a PM marker to check the purity of the purified membranes ( Fig.  Id) . The intrinsic fluorescence of GFP imparted to the fusion protein also enabled us to detect the wild-type and mutant Cdrlp proteins in live cells. Cdrlp-GFP expression at the cell periphery also confirmed that tbe GFP tagging of CdrIp did not interfere with its localization (data not shown). Tbe expression of Cdrlp-GFP was further confirmed by fluorescenceactivated cell sorting (FACS) analysis in which Cdrlp-GFP variant cells showed enhanced fluorescence intensity ( Fig. Ie) .
We ensured that GFP tagging and overexpression did not impair functional activity by analyzing drug susceptibilities of cells harboring CDRl or the GFP-tagged variant. It was found that the cells expressing Cdrlp or Cdrlp-GFP had similar levels of resistance to the drugs tested ( Fig. If) . The purified PM from PSCDRI-GFP cells containing Cdrlp-GFP also showed oligomycin-sensitive ATPase activity whicb was almost threefold higher (and comparable to the activity of overexpressed Cdrlp) than the activity of the PM protein isolated from the ADI-8u -control cells ( Fig. Ig) . Taken together, it was thus established that overexpressing Cdrlp and its GFPtagged variant is properly localized and functional. In the following experim, ents, these proteins were further examined for drug-and nucleotide-binding properties.
ELJICARYOT. C elL
Pbotoaffinity analogues of ATP and drug substrates bind to Cdrlp. Cdrlp utilizes A TP as an energy source by catalyzing its hydrolysis and coupling the energy released to the efflux of the drugs. Therefore, the binding of A TP to this protein can also be checked as a means of determining tbe functionality of this protein. The photoaffinity analogue, [a-32 PJ8-azido-A TP, has been used routinely for studying the interactions of nucleotide with the human P-gp, MRPI, and other ABC transporter proteins (4, 12, 45) . The binding of [a-32 PJ8-azido-ATP to Cdrlp was examined to see the interactions of ATP with the protein as detailed in Materials and Methods. Figure 2a shows that the incubation of purified PM proteins (IS !Lg) from ADI-8u -, ADl002, and PSCDRI-GFP cells with 10 ~ [a-32 PJ8-azido-ATP (10 !LCi/nmol) followed by UV irradiation led to covalent incorporation of this analogue (Fig. 2a, lane 3) . The labeling was competed out by I,OOO-fold excess A TP (10 mM), confirming that the observed binding was specific (Fig. 2a, lane 4) . The binding of [a-32 PJ8-azido-ATP to the Cdrlp-GFP variant protein was similar to that of native Cdrlp, which was also competed out by excess ATP (Fig. 2a , lanes 5 and 6). The control PM fraction from ADI-8u-cells did not show any band at the corresponding position ( Fig. 2a, lanes 1 and 2) . The specificity of 8-azido-ATP-, lAAP-, and azidopine-labeled bands (described below) corresponding to Cdrlp and Cdrlp-GFP in Fig.  2 was ensured by Western blot analysis. The t'M fraction labeled with either photoreactive analogue and/or substrate was run on a gel, which was then transferred to a nylon membrane. The blot was probed with Cdrlp antibodies, and tbe same blot was used to expose X-ray film. Tbe film was overlaid with the blot to confirm that the bands corresponded to Cdrlp and Cdrlp-GFP (data not shown). The binding of 8-azido-ATP analogue confirmed that Cdrlp or its variant Cdrlp-GFP overexpressed in this heterologous system is functionally active in terms of its ability to bind ATP.
In order to monitor drug-binding sites on human P-gp, radiolabeled pbotoactive analogs of prazosin and dihydropyridine have been us6d successfully (16, 6) . Such studies have revealed two major areas, one on each homologous half of the protein, as primary sites of drug interaction (6) . In this study, we used lAAP for analyzing interactions with Cdrlp. To analyze interactions with Cdrlp, 15 !Lg of purified PM proteins from ADI-8u-, AD1002, and PSCDR1-GFP cells was incubated with 3 to 6 nM [l25I]lAAP at room temperature for 5 min followed by UV cross-linking as detailed in Materials and Methods. Figure 2b (lane 2) shows that while lAAP specifically labeled Cdrlp, there was no binding of lAAP to the PM fraction prepared from control ADI-8u-cells (Fig. 2b, lane 1) . The binding of lAAP of Cdrlp-GFP variant PM was similar to that of native Cdrlp (Fig. 2b, lane 3) . In order to test whether the lAAP binding was specific, we performed binding with Cdrlp-GFP in the presence of molar excess cycloheximide, nystatin, anisomycin, and miconazole. Interestingly, IAAP was competed out by nystatin (100 !LM), a known substrate of Cdrlp (Fig. 2c, lane 4) , while the binding remained unaffected by the presence of the other drugs ( Fig. 2c , lanes 3, 5, and 6).
Azidopine, a dihydropyridine photoaffinity analog, has been shown to bind specifically to mammalian drug-transporting P-gps (37, 20, 26, 27) and is a valuable tool used in determining tbe substrate-binding sites on these multidrug transporters. We explored this possibility by examining the ability of azidopine
.. and PSCDR1-GFP (Cdr1p-GFP) cells were separated on an SDS-8% polyacrylamide gel (b), stained with colloidal Coomassie blue G-250 (c), electroblotted onto a nitrocellulose membrane and incubated with rabbit polyc\onal anti-Cdr1p antibody (diluted 1:500). Proteins were dett'cled with HRP-labeled anti-rabbit immunoglobulin using an ECL kit. (d) Expression of Pmalp. The PM proteins (20 I1g) from ADl-8u-, AD 1 002 (wild-type Cdrlp), and PSCDR1-GFP (Cdrlp-GFP) cells were separated on an SDS-8% polyacrylamide gel and probed with rabbit polyclonal anti-Pmal p antibody (diluted 1:10,000) to detect Pmalp expression as described above. The position of the corresponding loo-kDa band of Pma Ip on the gel is marked by an arrow. (e) Flow cytometry of cells expressing Cdrlp-GFP. ADI-8u-(control) and PSCDRI-GFP (Cdrlp-GFP) cells were grown to mid-log phase and used for FACS analysis as detailed in Materials and Methods. Analysis was performed with CeIlQuest software as described previously (44) . (f) Drug resistance profiles of ADl-8u-, PSCDRl-GFP, and ADl002 cells. The MICroS (in micrograms per milliliter) of the indicated drugs, anisomycin (Aniso), cycloheximide (Cyh), Huconazole (Flu), miconazole (Mic), and nystatin (Nys), for ADl-8u-, PSCDRl-GFP (Cdrlp-GFP), and ADl002 (wild-type Cdrlp) cells were determined as described in Materials and Methods. The results are typical of one determination, which was confirmed by three independent experiments. (g) Oligomycin-sensitive Cdrl p ATPase activity in purified PMs from AD1-8u-, PSCDRI-GFP (Cdrlp-GFP), and ADl002 (wild-type Cdrlp) cells. ATPase assay was performed by using PM proteins (100 I4¥ml) of ADl-Bu -, ADl002, and PSCDRI-GFP cells at 30·C for 10 min as described in Materials and Methods. The oligomycin-sensitive activity was determined as the difference in the ATPase activity in the presence or absence of 20 11M oligomycin. The values are given as the means :t standard deviations (error bars) for three independent experiments.
to bind to Cdrlp. The PM proteins (30 ILg) from ADl-8u -, AD1002, and PSCDRI-GFP cells were incubated with 0.5 I-LM [3H]azidopine for 5 min at room temperature and then photocross-linked. The incorporation of radioactivity in protein bands corresponding to Cdrlp and Cdrlp-GFP showed similar inte nsities, implying that [:lH]azidopine could bind to both proteins ( Fig. 2e ). The specificity of binding was assessed by the addition ot a 100 ILM concentration of cycloheximide, nystatin, anisomycin, or miconazole. Interestingly, eH]azidopine binding to Cdrlp-GFP was not inhibited by nystatin, as was the case with IAAP binding, but was instead found to be competed out by miconazole ( Fig. 2f ). Of note, the competi- tion by both the substrates was concentration dependent, which showed saturation and thus was specific. We used substrate concentrations for routine experiments, which showed maximum inhibition or competition ( Fig. 2d and g) .
Construction and expression of mutant variants of Cdrlp. A multiple-sequence alignment of human P-gp, the ABC drug transporter of S. cerevisiae (PdrSp), and C. albicans Cdrlp, Cdr2p, Cdr3p, and Cdr4p highlights the conservation of certain amino acid residues within TMSs and NBDs which may have a role in the functioning of these transporters (Fig. 3a) . Considering the functional importance of amino acid residues determined for other ABC drug transporters, particularly of human P-gp and PdrSp of S. cerevisiae, in this study we selected the equivalent of the most homologous or conserved residues of Cdr1p for point mutations (Fig. 3b ) as indicated. This was achieved either by replacing a conserved residue by another amino acid. such as in SSl. SS2, SS3, SS4, SSS. SS7, SS8, SS9, SS10,SSll,SS12,SSI3,SS14,SSIS.SS16.SS17,orSS18,orby deleting the residue altogether, as in SS6. In total, 18 mutations (SSl to SS18) were introduced in the different predicted domains spanning the entire length of Cdr1 and are highlighted in Fig. 3b .
Initially. all the mutations were introduced into the CDR! gene driven by its native promoter cloned in nonintegrative pYEURA3 plasmid (pSI2-3S) (36) . The hypersensitive ADI234S68 cells were then transformed with the mutated plasmids, and the positive clones were selected by their ability to grow on SD-URA plates. The positive transformants were further confirmed by Southern hybridization (data not shown). At least two positive clones of every mutant were selected for initial screening to rule out clonal variations.
Drug resistance profiles of mutant Cdrlps. Confirmed positive mutants designated SSI to SS18 were screened for their sensitivity to drugs by determining the lowest drug concentration that gave >80% inhibition (MIC 80 ) ( Table 2) and also by spot test (Fig. 4) . The mutants were classified into three groups according to their sensitivity to the drugs tested. Substitutions such as D232K (SSlO) and T13S1F (SSlS) and deletion of phenylalanine, tlF774 (SS6), resulted in a general drug-sensitive phenotype towards all the drugs tested. while strains with mutations F774A (SSS). G296D (SS11). G99SS (SSI2), GlOOOC (SSI4). C1418Y (SS16), Tl4491 (SS17), and V14S61 (SSI8) were selectively sensitive to one or more drugs compared to the wild type. Mutants, sllch as K309E (SSI), R308S (SS2), G30SA (SS3), G30SV (SS4), V773A (SS7), V7731 (SS8), D232E (SS9), and G998S (SS13), retained the hyperresistant phenotype comparable to wild-type Cdrlp-expressing cells (AD-CDRl).
In order to ascertain whether the introduced mutation in Cdrlp and the observed altered drug susceptibility were not due to poor expression or localization of the protein, we analyzed its expression in PM proteins by immunoblotting. It was observed that all the mutants except tlF774 (SS6) (discussed below) expressed the mutant variants of Cdrlps to the same level (data not shown).
As shown in Fig. 4 and Table 2 , the mutant variant SS5 (F774A) was sensitive to nystatin, cycloheximide, and fluconazole but showed marginal or no aiterations in drug susceptibilities towards other drugs tested (Table 2 ). However, the Cdrlp-harboring tlF774 variant in SS6 was found to be sensitive to all the drugs tested.
Site-directed mutagenesis in the overexpressed Cdrlp. In order to understand the molecular bases of the observed phenotypes of the two variant mutant Cdrlp-expressing cells (SSS [F774A] and SS6 [tlF774]), they were analyzed further in greater detail. To do this, the same mutations were introduced in the Cdrlp-GFP-overexpressing plasm ids (pPSCDRI-GFP). The mutated plasmids were integrated in S. cerevisiae (ADl-8u-) as described above. Southern hybridization was done using a CDR1-specific probe to ensure that the gene was inserted as a single copy at the genomic PDR5 locus (data not shown). The new overexpressing strains harboring mutant Cdrlp-GFP were designated SSSG (F774A) and SS6G (tlF774).
Drug susceptibility of SS5G (F774A) and SS6G (AF774). The cells overexpressing GFP-tagged Cdrlp variants were checked for their sensitivity to drugs. As shown in Table 3 , the SS6G (t:.F774) strain was significantly sensitive to all drugs tested, while the SS5G (F774A) s.train showed significant sensitivity to only nystatin: It should be pointed out that the difference in the fold sensitivity or resistance depicted in Tables 2 and 3 cannot be compared due to different expression strategies employe.d in these experiments ( Table 2 depicts data of a low-copy-number plasmid expression system, wbile Table  3 shows MICs of an integrative overexpression system).
ATPase activity of mutant Cdrlp-GFPs. The purified PM proteins from S$SG (F774A) and SS6G (tlF774) cells were analyzed for .heir oligomycin-sensitive ATPase activity. Of note, the oligomycin-sensitive ATPase activity was higher in all the PM fractions from cells expressing either native or mutant Cdrlp-GFP than in control ADI-8u -cells ( Fig. 5a ). However, the oligomycin-sensitive ATPase activity of SSSG (F774A) was comparable to that of native Cdrlp-GFP, while the specific activity of SS6G (tlF774) was -50% lower ( Fig. Sa) . However, considering the fact that the expression of the mutant Cdrlp-GFP in SS6G (tlF774) was -S% of the wild-type Cdrlp-GFP ( Fig. 6a ), tbe specific activity of mutant protein could actually be higher. It is important to mention that we were unable to detect drug-stimulated ATPase activity, although that would have been a correct measure of the ATPase activity contributed by the active protein. In fact, we and others have so far been unable to demonstrate drug-stimulated ATPase activity of any of the yeast ABC drug transporters (10, 33) . The amino acids are numbered according to their positions in the proteins. The positions of mutated residues in Cdrlp with respect to other protcins are marked with arrows, and the residues mutated in Cdrlp are boxed. Since there is no homology in the protcin sequences of Mdrl and Cdrl to Cdr4 proteins in CL5 and EL6, the Mdrl protein sequence has not been included in these alignments. (b) Locations of the mutations introduced into CDRl. The amino acid substitutions introduced by site-directed mutagenesis, the designation, and the location of mutation are indicated in the predicted topology model in Cdrlp. The mutants, which were tagged with GFP at the C-terminal end and overexpressed in S. cerevisiae, are boxed. Mutant Cdrlp-GFPs elicit reduced effiux of rhodamine 6G. We checked the rhodamine 6G efflux and found that both the mutants overexpressing GFP-tagged Cdrlp variants exhibited reduced efflux compared to cells expressing native protein. (Fig. Sb) .
Expression of mutant Cdrlp-GFPs. In order to ensure that the observed changes in drug susceptibilities and efflux activities of SS5G (F774A) and SS6G (aF774) were due to alterations in protein functions rather than due to altered expression levels, the steady-state levels of Cdrlp-GFP variants were compared to those of the native protein by Western blot analysis. The Western blot of these two overexpressing mutant Cdrlp-GFP PM proteins with anti-Cdrlp polyclonal antibody showed that SS5G (F774A) expressed mutant Cdrlp-GFPs to the same level as that of wild type (Fig. 6a, middle panel) .
.. ',. !'"IG. 4. Drug resistance profiles of wild-type and mutant CDRI strains determined by the spot and MIC assays. S6-20 (control) or AD-CDR 1 (expressing wild-type Cdr1p) cells or the Cdrlp mutants (SS1 to SS18) created by site-directed mutagenesis were grown overnight on SD-URA plates at 30°e. The cells were then resuspended in PBS to an A6()(J of 0.1. Five microliters of fivefold serial dilutions, namely, 1:5 (lanes 1), 1:25 (lanes 2), 1: 125 (lanes 3), and 1 :625 (lanes 4) dilutions of each strain were spotted onto SD-URA plates in the absence (control) or presence of the following drugs: anisomycin (Aniso) (1 f.lg/ml), cycloheximide (Cyh) (20 ng/ml), fluconazole (Flu) (2 J.l.g/ml), miconazole (Mic) (250 ng/ml), and nystatin (Nys) (500 ng/ml). Growth differences were recorded after incubation of the plates for 48 h at 30°e. Growth was not affected by the presence of the solvents used for the drugs (data not shown) . Hence, the observed functional defects observed in SS5G (F774A) expressing a mutant variant of Cdrlp were not due to an effect on the level of the synthesis or trafficking of these proteins. The PM fractions were probed for PM-ATPase with its antibodies on a Western hlot, which showed equal amounts of protein in all the PM fractions ( Fig. 6a, lower panel) . As revealed by immunoblotting with a monoclonal antibody against GFP, the mutant Cdrlp-GFP of SS6G (t.F774) was poorly expressed at the cell surface ( Fig. 6a, upper panel, lane  4) . Of note, this faint band of mutant Cdrlp-GFP from SS6G was picked up consistently when we used monoclonal antibody against GFP. The FACS analysis of the SS6G (t.F774) cells also showed poor cellular expression of mutant Cdrlp-GFP (Fig. 6b ). Confocal microscopy confirmed that there was considerably reduced cell surface expression of mutant Cdrlp-GFP in SS6G (t.F774) cells (Fig. 6c ). Thus, t.F774 Cdrlp-GFP mutant variant protein was consistently detected at a reduced steady-state level on the cell surface relative to native Cdrlp-GFP, suggesting that this mutation might harbor a defect which affects its surface localization (discussed below).
Characterization of ATP-and substrate-binding sites ofmutant Cdrlp-GFP variants. In order to explore whether the observed differences in drug susceptibilities accompanied by increased drug sensitivity and efflux activities were not due to any aberration in nucleotide or drug binding, these mutants were analyzed for their ATP-and drug-bindir.g abilities by using [ot-32 p]8-azido-ATP, [ '25 I]lAAP, and eH]azidopine.
[a-32 P]8-azido-ATP binding. The radiolabeled analogue of ATP, [ot-32 P]8-azido-ATP, was used to assess its binding to mutant Cdrlp-GFPs using the purified PM fractions from SS5G (F774A) and SS6G (t.F774) cells. It is clear from Fig. 6d that there was no significant difference in the ATP binding to VOL 2, 2003 Cdrlp 1371 however, specific in all the mutants carrying Cdrlp variants, as was evident from its competition by ATP (10 mM) ( Fig. 6d ) . e 25 I1IAAP and [3H1azidopine binding to mutant Cdrlp-GFPs. It was found that although mutant Cdrlp-GFP of SS5G (F774A) could bind [m I]lAAP, the variant showed 2.3-fold-greater binding than the native Cdrlp-GFP ( Fig. 6e ) . The drug-binding domains of mutant Cdrlps were further probed by examining the binding of eH]azidopine. It was observed that although [3H]azidopine binds to mutant Cdrlp-GFP from SS5G (F774A), [3H]azidopine binding to mutant Cdrlp-GFP from SS5G (F774A) was l.8-fold higher than that for wild-type Cdrlp-GFP ( Fig. 6f ). On the other hand, the mutant Cdrlp-GFP from SS6G (1lF774) showed a very faint specific band, which corresponded to very little protein at the cell surface of this mutant protein. Irrespective of the extent of eH]azidopine binding among mutant variants of Cdrlp-GFP, it could be competed out by miconazole (100 JJ.M).
The deletion of F774 leads to poor cell surface localization of the mutant Cdrlp-GFP in SS6G. The confocal images showed that while the expression of Cdrlp-GFP in the wildtype cells and of mutant Cdrlp-GFP in SS5G (F774A) cells at the cell surface ( Fig. 6c ) was comparable, it was minimal in SS6G (1lF774) cells. Although some of the fluorescent protein was visible in the cytoplasm of SS6G (1lF774) cells, very small patches of fluorescence were seen on the cell surface, which showed that probably the mutant Cdrlp-GFP in SS6G (1lF774) cells was not properly localized on the cell surface. These results were corroborated by Western blot analysis where PM of SS6G (1lF774) cells also showed significantly reduced expression of mutant Cdrlp-GFP ( Fig. 6a ). FACS analysis of the live cells showed fluorescence in SS5G (F774A) cells that was comparable to that of the wild-type PSCDR1-GFP cells. SS6G (1lF774) cells, however, showed lower fluorescence intensity, but it was still higher than that of the control cells (ADI-8u -) ( Fig. 6b ). The mean fluorescence intensities (in arbitrary units) for wild-type PSCDRI-GFP, SS5G (F774A), SS6G (1lF774), and ADI-8u -cells were 500, 482, 160, and 11, respectively. Taken together, these results suggest that there was only marginal expression of mutant Cdrlp-GFP in the PM of SS6G (1lF774) cells, which was probably sufficient to show some functional activity (Fig. 5a and b and Fig. 6 ); the functional activity was lower than that of the wild type but not sufficient to confer drug resistance ( Fig. 4 and Table 2 ).
Mutant AF774 Cdrlp-GFP can be brought to the cell surface by growing cells in the presence of the Cdrlp substrate. In the following experiment, we explored various possibilities related to poor surface expression of the SS6G (1lF774) protein variant. The poor surface expression of the SS6G (111'774) protein could be due either to poor localization, reduced expression of protein, or rapid degradation of protein. We checked whether the localization of mutant Cdrlp-GFP in SS6G (1lF774) cells could be improved. To do this, we added different drugs, which are substrates of Cdrlp, such as cycloheximide, miconazole, anisomycin, and nystatin (at concentrations lower than their respective MICs), just after the lag phase of the SS6G (1lF77 4) cells (4 to 5 h). The cells were then grown for 12 more hours. Thereafter, cells were checked by confocal microscopy for the localization of the protein. It was observed that the mutant Cdrlp-GFP protein showed improved surface localization with increasmg concentrations of cycloheximide. The surface ex 'Pression of mutant Cdrlp-GFP was almost identical to that of native Cdr1 p-GFP at 40 ng of cycloheximide per rnJ ( Fig. 7a to h) . FACS analysis also confirmed that the surface expression of SS6G (1lF774)-expressing Cdrlp-GFP mutant grown in the presence of 40 ng of cycloheximide per ml was similar to that of the wild type (Fig. 7i ). Interestingly, PM protein isolated from the SS6G (1lF774) cells, which were grown in increasing concentrations of cycloheximide and subjected to SDS-PAGE and Western blot analysis (probed with monoclonal anti-GFP antibody), also showed a concentration-EUKARYOT. CELL dependent increase in the amount of Cdrlp-GFP in the PM fraction, which peaked at 40 and 50 ng/ml ( Fig. 7j and k, lanes  6 and 7) . Under these conditions, SS6G (1lF774) cells expressing mutant variant distinctly showed improvement in surface localization, while the presence of drug had no effect in cells expressing native Cdrlp-GFP ( Fig. 7b, h, and i) . The observed rescuing effect was not specific to cycloheximide alone. Other substrates of Cdrlp, such as anisomycin and nystatin, could also rescue the 1lF774 protein to the PM (dat;l not shown).
Mutant Cdrlp-GFP from SS6G (AF774) cells grown in the presence of cycloheximide is functional. In order to test whether improved localization led to the resumption of transport functions, the efflux of rhodamine 6G was measured in cells grown in the presence of cycloheximide. The control (ADl-8u-), PSCDRI-GFP, and SS6G (1lF774) cells were grown in the presence or absence of cycloheximide (40 ng/ml) for 12 to 14 h, and rhodamine 6G efflux was studied as described in Materials and Methods. Figure 71 shows that the SS6G (1lF774) cells grown in the presence of cycloheximide showed considerable increase in rhodamine 6G efflux over the same cells gfown in the absence of cycloheximide. The level of efflux was comparable to that of native PSCDRI-GFP cells grown at the same concentration of cycloheximide. There was sc.me reduction in the efflux of rhodamine 6G by PSCDR1-GFP cells grown in the presence of cycloheximide. The decrease in efflux by the cells expressing native Cdrlp could be due to the fact that cycloheximide, which is also a substrate for the Cdrlp transporter, probably competes with rhodamine 6G.
DISCUSSION
Cdrlp was first cloned and identified as a protein capable of effiuxing a variety of unrelated cytotoxic drugs and subsequently demonstrated to be a transporter involved in azole resistance of C. albicans (24, 36) . Further studies from our laboratory as well as from other research groups established that the efflux of drugs by Cdrlp represents one of the major determinants of azole resistance in clinical isolates of C. albicans (24, 38) . Functional analysis of Cdrlp further revealed that in addition to drug extrusion activity, the protein is also capable of effluxing human steroid hormones and can translocate membrane phospholipids between the two monolayers of PM of C. albicans cells (13, 24) . The promiscuity of Cdrlp towards substrates and its ability to mediate several functions suggest that the protein might contain mutually exclusive substrate-binding sites that allow the efflux of a variety of unrelated compounds with striking physical and chemical diversity. The molecular basis for the broad range of this transport capacity is largely unknown for Cdrlp as well as for other ABC drug transporters of yeast. Delineating the architecture of the drug-binding sites of Cdrlp for the substrates will be invaluable not only to understand how drugs interact with this protein but also to design more useful and specific inhibitors of Cdrlp. In this study, we have attempted to examine the relationship between structure and functinn for Cdrlp.
Cdrlp is fully active as a GFP-tagged protein. For detailed functional analysis, Cdrlp tagged with GFP was overexpressed from a genomic PDR5 locus in a S. cerevisiae ADl-8u -mutant derived from a pdrl-3 mutant strain with a gain-of-function mutation in the gene encoding transcription factor PDRJ , re- suiting in a constitutive hyperinduction of the PDR5 promoter (33) . Thus. Cdrlp-GFP expression driven by hyperinduced PDR5 promoter provided a sufficient level of expression, confirmed by confocal microscopy, flow cytometry analysis, and irnmunoblotting. for functional analysis. That GFP-tagged Cdrlp was functional like native Cdrlp was established by assaying the MICs of various drugs for S. cerevisiae host cells.
The fluorescence imparted by GFP-tagged Cdrlp visualized with a confocal microscope confirmed its proper localization to PM.
Cdrlp harbors multiple drug-binding sites. Cdrlp, Pdr5p, human P-gp, and some of the MRPs function as drug extrusion pumps. Cdrlp differs structurally from the human full-length ABC transporters. since it possesses inverted domain organization [(NBD-TMDhl (36) compared to human P-gp [(TMD-NBDhl (15) . However. for the human ABCG2 (the mitoxantrone resistance-associated protein MXR, the breast cancer resistance protein BCRP, or the placenta ABC protein' ABCP), the domain organization of the half transporter is similar to that of Cdrlp (25) , and the functional unit of this transporter is a dimer [(NBD-TMDhJ. Notwithstanding these domain-based differences and low level of sequence identity outside conserved stretches, the binding characteristics of Cdrlp have many commonalties with those of human P-gp. The binding of IAAP as well as azidopine to Cdrlp is one such case of similarity. Both analogues bind to human and murine drug-transporting P-gps and Cdrlp (this study), where it has been used to map drug-binding sites (17) . The fact that IAAP binding to Cdrlp is competed out by nystatin, while miconazole did not have any effect, and the fact that azidopine binding is competed out onJy by miconazole ( Fig. 2c and f) suggest that IAAP and azidopine share two different binding sites in Cdrlp. We had earlier observed that the deletion of a 79-amino-acid stretch from the C-terminal end, which encompasses the TMS12 of this transporter, leads to selective impairment of drug resistance (23) . The expression of ~Cdrlp led to decreased resistance to nystatin, while resistance to miconazole was retained. Recently, by using a variety of novel sub-strates of Pdr5p, Goiin er ai. (i4) have reported that this ABC drug transporter from S. cerevisiae has at least three drugbinding sites and suggested that some substrates might even interact at more than one site. Taken together, our results suggest that Cdrlp harbors different drug-binding sites, which recognize structurally dissimilar drugs. Of note, selective sensitivity to nystatin and miconazole revealed upon mutational analysis further reaffirmed that Cdrlp has multiple drug-binding sites. While variant F774A retained the resistance to miconazole compared to native Cdrlp, its sensitivity towards nystatin was increased considerably ( Fig. 4 and Table 2 ). This duality of Cdrlp towards these two drugs can be explained if one considers different binding sites. Interestingly, a similar conclusion can be drawn from lAAP and azidopine binding. While the former gets competed out by nystatin, the latter is affected by miconazole. Taken together, this would suggest that nystatin and lAAP share common binding site(s), while azidopine and miconazole bind to another site. The concept of multiple drug-binding sites is further illustrated by the fact that the binding of lAAP and azidopine are not competed out by drugs, such as cycloheximide, anisomycin, and fluconazole, which may bind to an as yet unidentified site(s).
Notwithstanding topological differences, the photoaffinity analogues (lAAP and azidopine) could specifically label Cdrlp as well as human P-gp. The extent of binding of these photoaffinity analogues to Cdrlp revealed even more similarity between the two ABC drug transporters. F{)r example, both lAAP and azidopine showed enhanced binding to Cdrlp-GFP variant of SS5G (F774A). Similar observations were reported by Chen et a!. (7) , who observed that the deletion of F335 led to enhanced lAAP binding to P-gp. In another study, Loo and Clarke (26) observed that the replacement of F335 by A of human P-gp also led to enhanced binding of azidopine. Taken together, these results suggest that F335 in TMS6 of mammalian P-gp and its equivalent F774 in TMS6 of Cdrlp behave similarly and play an important role in determining substrate specificity. AF774 in SS6G leads to poor localization of mutated Cdrlp. In order to analyze some of the interesting mutant variants of Cdrlp, F774A and ~F774 mutations were introduced into the Cdrlp-GFP expression system driven by hyperinduced PDR5 promoter ( discussed above) for detailed analysis. It was observed that in the SS6G (~F774) strain, in which F774 of the predicted TMS6 was deleted, showed very low expression of mutant Cdrlp-GFP in the PM fraction when analyzed by Western blot analysis. While mutant Cdrlp-GFP in SS6G (~F774) cells was poorly expressed in PM fractions isolated from these cells, Western blotting did not show any steady-state expression defect in SS5G (F774A) membranes. Confocal microscopy and F ACS analysis also confirmed poor expression of SS6G (~F774) mutant protein.
Cell surface expression of mutant Cdrlp (J1F774) protein could be rescued by growth in the presence of cYcloheximide. In the case of the SS6 mutant, one cannot exclude the possibility of poor protein localization in the PM due to either low protein levels or its degradation. However, since the protein can be rescued to the cell surface by growing the mutant cells in the presence of substrates, such as cycloheximide (at a concentration that does not affect growth and protein synthesis), it is probable that the mutant protein is not properly localized.
EUKARYOT. CELL
Of note, the mutant protein of ~F774 which could be directed to the PM in the presence of cycloheximide was not only found to be at the cell surface but also became functionally active, as determined by its ability to efflux rhodamine 6G. These results suggest that the deletion mutation ~F774 in TMS6 inhibits the transporter from folding into an active conformation, but the protein can be made to fold into an active conformation if synthesized in the presence of cycloheximide.
Earlier misprocessing of ABC transporters has also been observed. For example, the deletion of phenylalanine 508 in NBDI of the cystic fibrosis transport receptor (CFTR) causes its improper localization on the cell surface (8) . Deletion of an equivalent phenylalanine residue in NBDI of Yorlp of S. cerevisiae also led to a variant protein, which was retained in the endoplasmic reticulum (21) . Interestingly, a number of lowmolecular-weight molecules have been shown to rescue the processing defect of mutant CFTR protein (5) . In addition, even lower temperatures or the presence of glycerol, trimethylamine N-oxide, or deuterated water has been shown to rescue the ~F508 CFTR mutant misprocessing phenotype (11, 43) . Similarly, the TMS6 mutant of human P-gp expressing misfolded protein was rescued when grown in the presence of substrates, such as cyclosporine A, capsaicin, vinblastine, or verapamil (28) . In such rescues, an early interaction between the drug substrate and TMD is observed; this stabilizes the folding intermediates in a native conformation, thus escaping cell quality control mechanism. The exact mechanism by which cycloheximide.rescues the misprocessed ~F774 mutant variant . of a:rlp is not clear at present. However, given the clinical importance of this protein, such residues, which affect the localization, could be exploited in rationally designing antifungal agents.
Taken together, in this study, we have characterized Cdr1p by overexpressi·ng it as a GFP-tagged protein in S. cerevisiae.
We shew that the photoaffinity analogs lAAP and azidopine specifically bind fo Cdrlp. The analysis of GFP-tagged mutant variants of Cdrlp revealed that the deletion of a conserved F774 in predicted TM6 led to poor surface localization of the protein. The mislocalized ~F774 mutant Cdrlp could be rescued to the PM as a functional transporter by growth in the presence of a Cdrlp substrate, cycloheximide. In addition, our study demonstrates that there is a conserved functional homology between Cdrlp and human P-gp. For example, similar to Pgp, TMS6 in Cdrlp also appears to be a major contributor to drug substrate-binding sites. Considering the clinical importance of MDR in cancer patients and fungal infections, structure-and-function study Of Cdrlp should provide additional information about the mechanism of action of these yeast and mammalian drug transporters. In this study, we examined the importance of membrane ergosterol and sphingolipids in the drug susceptibilities of Candidil albicans. We used three independent methods to test the drug susceptibilities of erg mutant cells, which were defective in ergosterol biosynthesis. While spot and filter disk assays revealed that erg2 and erg16 mutant cells of C. albicans became hypersensitive to almost all of the drugs tested (i.e., 4-nitroquinoline oxide, terbinafine, o-phenanthroline, itraconazole, and ketoconazole), determination of the MIC at which 800/0 of the cells were inhibited revealed more than fourfold increase in susceptibility to ketoconazole and terbinatine. Treatment of wild-type C. albicans cells with fumonisin Bl resulted in 45% inhibition of sphingolipid biosynthesis and caused cells to become hypersensitive to the above drugs. Although erg mutants displayed enhanced membrane Ouidity and passive dilfusion, these changes alone were not sufficient to elicit the observed hypersusceptibility phenotype of erg mutants. For example, the induction in vitro of a 12% change in the membrane fluidity of C. albicans celJs by a membrane Ouidizer, benzyl alcohol, did not alfect the drug susceptibilities of Candidil cells. Additionally, the surface localization of green Ouorescent protein-tagged Cdrlp, a major drug efHux pump protein of C. albicans, revealed that any disruption in ergosterol and sphingolipid interactions also interfered with its proper surface localization and functioning. A 50% reduction in the efHux of the Cdrlp substrate, rhodamine 6G, in erg mutant cells or in cells with a reduced sphingolipid content suggested a strong correlation between these membrane lipid components and this major efHux pump protein. Taken together, the results of our study demonstrate for the first time that there is an interaction between membrane ergosterol and sphingolipids, that a reduction in the content of either of these two components results in a disruption of this interaction, and that this disruption has deleterious elfects on the drug susceptibilities of C. albicans cells.
Candida albicans is an opportunistic diploid fungus that causes infection in immunocompromised and debilitated patients (30) . The widespread and prolonged usage of azoles in recent years has led to the rapid development of the phenomenon of azole resistance, which poses a major threat to antifungal therapy (27, 46) . Various mechanisms which contribute to the development of azole resistance in Candida have been implicated; these include the overexpression of or mutations in the target enzyme of the azoles, lanosterol 14a-demethylase, as well as the overexpression of genes encoding drug efflux pumps belonging to the ATP-binding cassette (ABC) superfamily, namely, CDRl and CDR2, and transporters belonging to the major facilitator superfamily (MFS), namely, MDRI (1, 10, 11, 16, 30, 31, 45) .
. It has been shown by various investigators that the action of antifungal agents is modulated by subtle modification of the membrane lipid composition (14, 16, 22, 28) . Of note is that clinical as well as adapted azole-resistant isolates of C. albicans exhibit altered membrane phospholipid and sterol compositions (16, 22) . Among various classes of yeast lipids, membrane t Kasturi Mukhopadhyay and Tulika Prasad contributed equally to this work. 1778 sterol, which is also the target of azoles, is one of the important constituents; it is responsible mainly for rigidity, stability, and resistance to physical stresses (32) . Therefore, a loss of sterol generally results in destabilization of the membrane, leading to increased membrane permeability and altered drug susceptibilities of yeast cells (28, 32) . The sphingolipids of C. albicans are another class of important membrane lipid components; they differ from those of mammalian cells in that they are structurally less complex and contain phosphatidylinositol as part of their polar head groups (6, 20) . These observations acquire significance when one considers recent reports which show the existence of discrete membrane microdomains, known as lipid rafts and composed predominantly of sphingolipid and sterol, within lipid bilayers (4, 5, 19, 26, 37, 38, 48) . Interestingly, the up-regulation of lipids and proteins that constitute lipid rafts and the caveolar membrane has been observed in drug-resistant mammalian cells (18, 19) . Additionally, it was recently reported that human P glycoprotein! multidrug resistance protein (Pgp/MDR1) , which is a homologue of ABC drug transporter Cdrlp of C. albicans, is localized predominantly in cholesterol-enriched membrane domains, and that the depletion of cholesterol impairs human Pgp/MDRI-mediated drug transport (5, 23) . Taken together, these findings suggest that sphingolipids and sterol as individual components as well as their mutual interactions play an important role in the functioning of the ABC drug efflux pump proteins (9, 13, 19, 21, 35) . In order to explore the interactions between sphingolipids and ergosterol (a substitute for mammalian sterol) and their involvement in the drug resistance of C. albicans, we exploited two sets of conditions in this study. We used erg mutants of C.
albicans, which were deficient in ergosterol content, and we also used C. albicans cells with reduced sphingolipid content resulting from a selective blockage of sphingolipid synthesis. We observed that a reduction in either of these two major membrane lipid constituents had deleterious effects on drug resistance, in that Candida cells became hypersensitive to most of the drugs tested. Our results further suggest that ergosterolsphingolipid interactions are important determinants of the surface localization of the major drug extrusion pump protein Cdrlp, which in turn affects the drug susceptibilities of C. Yeast strains and growth medJa. C. albicans strains ATCC 44829 (wild type, 33 ERG+ ade -), ATCC 44830 (ergJ6 ade-), and ATCC 44831 (erg2 ade-) were procured from the American Type Culture Collection. The strains were main-tained as described previously (2) . The Saccharomyces cerevisiae strain used was PSCDRI-GFP (an ADl-8u -derivative expressing Cdrlp-green Huorescent protein [GFP]) (36) . The yeast strain was cultured in YEPD broth (Bio 101 Vista, Calif.) or SD-URA -medium (Bio 101).
Drug susceptibility testing of C. albicans strains. Drug susceptibilities we re measured by using microliter plate, spot, and filter disk assays. The MICs for the strains were determined with a broth microdilution method as described previ· ously (28) . For the spot assay, 5-111 samples of fivefold serial dilutions of each yeast culture (each with cells suspended in normal saline to an optical density at 600 nm [OD 600 ] of 0.1) were spotted onto YEPD plates in the absence (control) or in the presence of the following drugs: 4-nitrtlquinoline oxide (0.1 ",glmI), terbinafine (0.4 ",glml), o-phenanthroline (4 ",glmI), fluconazole (0.4 ",glml), itraconazole (0.1 ",glmI), and ketoconazole (0.02 ",glm!). Growth differences were recorded following incubation of the plates for 48 h at 300C. The filter disk assay was done as described earlier (28) ; the following drugs were spotted in a volume of 5 to 10 ",I: 4-nitroquinoline oxide (3 ",g), terbinafine (16 ",g), 0phenanthroline (64 ",g), 8uconazole (32 ",g), itraconazole (20 ",g), and ketocon· azole (2 ",g).
labeling of spheroplasts for experiments involving fluorescence recovery after photobleaclting (FRAP). Spheroplasts were suspended at a density of lOS cells/ml in 1 M sorbitol-O. l M EDTA bulIer and labeled with FAST-Dil. Labeling was carried out by using a final concentration of 10 ",M FAST-Dil with 2% residual ethanol in glass tubes in the dark for 30 min at 2SoC with mild .shak. ing. The final pellet of spheroplasts was resuspended in a small volume of 1 M sorbitol-O.l M EDTA buffer. One drop of this suspension was mounted between a glass slide and a coverslip which had been previously coated with 0.1 mg of poly-o-Iysine/ml. The coverslip was sealed with nail enamel and placed inverted on tbe microscope stage for FRAP experiments. Fluorescence polarization studies. Steady-state 1luorescenre polarization studies of C. albicans reUs with the 1luorescent probe DPH were carried out essentially as described earlier (28) . Drug dilfusion and elOux assays. (I) Passive dilfusion. Passive diffusion of the Ouoresrent compound R6G and 3H-labeled Ouconazole was determined by using a previously described protocol (28) .
(il) R6G elOux. The functionality of Cdrlp was checked by assaying the energydependent efflux of R6G, a known substrate of tltis drug extrusion pump protein.
The protocol for the efflux assay was described previously (16) .
Labeling of cells with NBD-SM. Labeling of rells with NED-SM was carried out essentially as described earlier (28) .
Estimation of sphingolipid synthesis. The assay for sphingolipid synthesis was carried out as described by Mandala et aJ. (25) .
RESULTS
erg mutants of C. albicans are susceptible to various drugs. C. albicans mutants defective in ergosterol biosynthesis were isolated earlier by Pesti et al. (33) . These mutants were exploited in this study to examine whether the r~uction in ergosterollevels in any way affects the drug susceptibilities of C. albicans cells. As a first step, the lack of ergosterol in erg mutant cells was confirmed by reverse-phase high-pressure liquid chromatography (HPLC) and spectroscopic methods (data not shown). We used three independent methods (spot, microtiter plate, and filter disk assays) to examine the drug susceptibilities of erg mutant cells ( Fig. 1 and Tables 1 and 2 ).
We observed that in spot assays, the mutants sbowed increased susceptibilities to 4-nitroquinoline oxide, terbinafine, o-phenantbroline, itraconazole, and ketoconazole; however, data on the MICs at which 80% of the cells were inhibited (MICso) ( Table 1) showed that the erg mutants were hypersensitive only to terbinafine and ketoconazole (more than twofold). In order to further confirm the susceptibilities of the erg mutants, we measured the zones of inhibition obtained in filter disk assays. As shown in Table 2 , filter disk assays confirmed the finding of the spot assays ( Fig. 1 ) that erg mutants of C. albicans were hypersensitive to all of the drugs tested, with the exception of fluconazole. Tbese results emphasize that variations between drug susceptibility assays can exist (8) and that multiple drug susceptibility assays therefore should be used for exact assessment. Of note is that when equal number of cells were spotted on YEPD plates in the absence of drugs, erg mutant cells were found to grow relatively slowly, but this minor difference in growth rates did not affect the conclusions with regard to their susceptibilities to drugs. The difference in the rates of growth of erg mutant cells with or without drugs was very distinct, clearly indicating that erg mutant cells were (20) Ketoconazole (2) Wild type erg2 ° Drugs were spotted at the indicated concentrations in a volume of 5 to 10 .,.1.
hypersensitive, a finding which was also supported by the results of filter disk assays. Membranes of erg mutants are more fluid. In order to ascertain the change in membrane fluidity in erg mutants, we used the FRAP technique, in which the lateral mobility of a lipid probe (FAST-Oil) for C. aLbicans wild-type and erg mutant strains was determined. The fluorescence distribution of spheroplasts labeled with FAST-Dil is shown in Fig. 2A , panel c; the same field is viewed under phase contrast in Fig. 2A , panel b. There was no observable difference in the surface fluorescence distributions of FAST-DiI between wild-type and mutant strains ( Fig. 2A, panels d spheroplasts labeled predominantly at the plasma membrane ( Fig. 2A , panels b and c) were analyzed as described by Koppel et al. (17) . Representative fluorescence recovery plots for C.
albicans wild-type and erg mutant strains are shown in Fig. 2B . The absence of ergosterol in the C. albicans erg mutants was accompanied by an increase in the diffusion coefficient of FAST-Dil (Fig. 2C) . The increases in the diffusion coefficient of FAST-Oil and fluorescence polarization values (a decrease in fluorescence polarization values implies higher fluidity) demonstrate that erg mutants have more fluid membranes ( Fig.   2C and 0) . Thus, the results of two independent fluidity measurements confirm that the membranes of erg mutants of C. albicans are more fluid . tant cells in which active transport was blocked. We used fluorescent R6G and 3H-labeled fluconazole as described previously (28) as probes to monitor passive diffusion. The R6G distribution was determined by measuring the change in the absorbance values for supernatants withdrawn at various times. Figure 3A shows that both erg mutants had reduced concentrations of extracellular R6G in the supernatants over time.
These results imply that the passive diffusion of R6G is faster in erg mutants than in the wild type. Similar results were obtamed when we used 3H-labeled fluconazole to monitor fluconazole accumulation in energy-depleted cells. It is apparent from Fig. 3B that due to enhanced diffusion, the cells of both erg mutants accumulated larger amounts of fluconazole than did wild-type cells. The enhanced passive diffusion of R6G and fluconazole by erg mutants indicates that the mutants are more permeable, a property that could explain their hypersensitivity to drugs.
In vitro-induced changes in membrane fluidity do not affect drug resistance. In order to determine whether increased membrane fluidity and permeability alone was responsible for the altered drug susceptibilities observed in Candida erg mutants, we manipulated the fluidity of membranes of wild-type Candida cells in vitro by using a known membrane fluidizer, benzyl alcohol (BA) (28, 34, 39) . The addition of 25 mM BA led to a 12% increase in the membrane fluidity of Candida wild-type cells (Fig. 3C ). However, this BA-induced change in membrane fluidity did not alter susceptibilities to the drugs tested (Fig. 3D) . Note that the cause of fluidity changes induced by BA is different from that observed in erg mutant cells.
Nonetheless, the two experiments suggest that changes in flu-VOL. 48, 2004 A}_1~ ____________ ~ = §.
(;' 10 ~ 8
.. idity alone were not sufficient to cause the changes in drug susceptibilities that we observed.
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NBD-SM is readily exchangeable from erg mutants. In view of the interactions of membrane sterol and sphingolipids, observed particularly in membrane microdomains or rafts in other organisms (3, 4) , we attempted to explore the occurrence of such interactions in the membrane of Candida cells. We labeled Candida wild-type and erg mutant cells with fluorescent NBD-SM as described earlier (28, 40) . The main advantage of this fluorescent lipid analogue is that it can be readily inserted into biological membranes by spontaneous lipid exchange from exogenous carriers (15, 40) . Thus, at 90 min postlabeling, when NBD-SM incorporation into the Candida membrane was found to be at the maximum (data not shown), the cells were washed and the NBD-SM of labeled cells was back extracted with fatty acid-free bovine serum albumin (BSA). Figure 4 depicts the exchangeable NBD-SM from Candida wild-type and mutant cells. It was apparent that the amount of NBD-SM back extracted with BSA from erg mutant cells was much higher than that from wild-type cells (Fig. 4 ). This finding would mean that ergosterol depletion in erg mutant cells results in disruption of the interactions between ergosterol and sphingomyelin and thereby leads to enhanced exchangeability of sphinogomyelin. Interestingly, the exchange of NBD-SM was considerably reduced (restored to the level in wild-type cells) when erg mutant cells were grown in ergosterol-supplemented media (Fig. 4) .
Drug susceptibilities of C. aIbicans cells are aJl'ected by fluctuations in sphingolipid content. In order to explore whether the drug susceptibilities of C. albicans cells are also affected by membrane sphingolipid levels, we used fumonisin Bl, an inhibitor of sphingolipid biosynthesis which blocks the formation ANTIMICROB. AGENTS CHEM01llER.
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Palmitoyl-CoA + Serine of phytoceramide from phytosphingosine and thus inhibits the synthesis of the major sphingolipids (Fig. 5A ). Wild-type C. albicans cells grown in the presence of 50 and 100 j.LM fumonisin Bl had 45 and 55% reductions in sphingolipid synthesis, respectively (data not shown). Interestingly, the reduction in sphingolipid content due to the blockage of sphingolipid synthesis by fumonisin Bl caused wild-type C. albicans cells to become hypersensitive to most of the drugs tested (Fig. 5B ).
The effect of fumonisin Bl on erg mutant drug susceptibilities was variable. While erg2 mutant cells showed no further significant change in drug susceptibilities in the presence of the inhibitor, erg16 mutant cells showed even higher susceptibilities to some of the drugs (Fig. 5B) . Of note is that the ergosterol content and membrane fluidity of C. albicans in the presence of fumonisin Bl did not change significantly (data not shown). Thus, the observed hypersensitivity of fumonisin Bltreated wild-type cells to various drugs could be attributed solely to reduced sphingolipid content. It appears that membrane lipid constituents, particularly ergosterol and sphingolipids, are able to independently affect the drug susceptibilities of C. albicans cells. These observations acquire significance when one considers the interactions between membrane sterol and sphingolipids (discussed below). Depletion of ergosterol or spbingolipids leads to poor surface localization of GFP-tagged Cdrlp. It was observed earlier that Cdrlp functioning was susceptible to the membrane lipid environment and, particularly, that the depletion of ergosterol had deleterious effects on drug susceptibilities (28, 41) . The localization of Cdrlp in membrane rafts has not been unequivocally established, but based on the interactions between ergosterol and sphingolipids (membrane raft components) and their effects on drug susceptibilities, it is very likely that Cdrlp, a drug transporter protein, is localized in such domains.
In order to examine whether the depletion of ergosterol or sphingolipids would in any way affect the surface localization of Cdrlp and thus in tum its functioning, we used an S. cerevisiae expression system that was developed by Nakamura et al. (29) and that was a generous gift from R. D. Cannon, University of Otago, Dunedin, New Zealand. ADl-8u-, from which seven major ABC transporters have been deleted, was derived from apdrl-3 mutant strain that causes hyperinduction of the PDR5 promoter. We achieved a high level of expression of Cdrlp-GFP by integrating the Cdrlp-GFP open reading frame at the PDR5 locus downstream from the PDR5 promoter in strain ADI-8u-; the resulting strain was designated PSCDRI-GFP (36) . , and strain PSCDRI-GFP incubated with 5 ILg of filipin/ml for 2 h (C). Cells were grown overnight and viewed directly for GFP f1uoresceoce 00 a glass slide under a x100 oil immersion objective in a Radiance 2100 (AGR3Q/BLD; Bio-Rad) confocal microscope equipped with 488-nm excitation and 500-to 530-nm band-pass emission filters. The flu orescence signa l from strain PSCDR1-GFP showed the localization of Cdr1p on the plasma membrane. On treatment with Fum Bl or extended incubation with filipin , the GFP fluorescence from strain PSCDRI-GFP appeared to be concentrated inside the cells, indicating poor surface localization of Cdrlp. The right panels show the merge of the left and middle panels.
the GFP fluorescence appeared to be concentrated inside the cells, implying poor surface localization of Cdrlp. Incubation with the polyene antibiotic filipin for an extended period of time was shown earlier to induce deformations and distortions in sterol-containing membranes (7, 12, 44) because filipin is known to interact with the 3-~-hydroxyl group of sterols. To examine whether filipin-induced distortions would in any way affect Cdr1p localization, we checked the localization of the GFP-tagged protein by confocal microscopy after extended incubation of the cells with filipino Figure 6C shows that th. e surface localization of Cdrlp was affected by extended filipin treatment and that this mislocalization was comparable to that seen in fumonisin B1-treated cells (Fig. 6B ). It is apparent that the disruption in vitro of interactions between ergosterol and sphingoJipids by either filipin or fumonisin Bl results in improper surface localization of Cdrlp.
Sphingolipid and ergosterol depletion results in reduced elHux ofR6G. Since the surface localization of Cdrlp appeared to be defective in cells in which interactions between ergosterol and sphingolipids were disrupted, we examined the functionality of this drug extrusion pump by measuring the efflux of R6G. R6G is a known substrate of Cdr1p and was used earlier to monitor the drug efflux activity of this drug transporter (16, 24) . R6G was allowed to enter deenergized Candida cells by passive diffusion. The energy-dependent extrusion of R6G then was initiated by the addition of glucose. The concentration of extruded dye in the supernatant was measured by monitoring its absorbance at 527 Dm. It is apparent from Fig. 7A that the concentration of extruded R6G in the supernatant was lower in both erg mutants than in the wild type. Similar results were obtained when we examined R6G efHux in wild-type cells treated with various concentrations offumonisin Bl (Fig. 7B) . The inhibitor-treated cells showed much less dye in the supernatant, suggesting reduced Cdrlp-mediated efHux (Fig. 7B) .
The results indicate that the disruption of interactions between ergosterol and sphingolipids in the membrane results in reduced efHux activity of Cdrlp.
DISCUSSION
Our study demonstrates that C. albicans erg mutant cells, which are defective in ergosterol synthesis, are hypersensitive to drugs. The increased drug susceptibilities shown by the erg mutant cells were not found to be merely due to an enhancement in membrane fluidity and passive diffusion of drug molecules across the plasma membrane. Rather, the lack of ergosterol in the erg mutant cells, which disrupted or destabilized the interactions within ergosterol-sphingolipid-rich rnicrodomains, was the main cause of the observed hypersensitivities of erg mutant cells.
In support of the above conclusion, we observed a close relationship between membrane ergosterol-sphingolipid interactions and drug susceptibilities of C. albicans. We found that a reduction in sphingolipid levels by the blockage of sphingolipid synthesis also caused C. albicans cells to become hypersensitive to various drugs. Further, the depletion of either one of the membrane lipid components appeared to affect the other. For example, we observed that erg mutants lacking ergosterol had larger amounts of exchangeable sphingolipids tban did tbe wild type (Fig. 4) . Evidence that sphingolipid content can affect the drug susceptibilities of yeast cells was recently reported elsewhere (13) . In that study, it was found that IPTJ gene transcription was responsive to Pdrlp/Pdr3p transcription factors that regulate pleiotropic drug resistance genes of S. cerevisiae. The IPTJ gene encodes the last step of sphingolipid biosynthesis, the loss of which has been shown to have differential effects on drug resistance phenotypes. An interaction between the two membrane lipid components was also evident from several other independent studies in which sphingolipid biosynthesis was shown to be coordinately regulated with cholesterol metabolism in higher eukaryotes (42, 43, 47) .
It is important to mention that human Pgp/MDR1 is preferentially localized in rnicrodomains (membrane rafts) rich in cholesterol and sphingolipids in the plasma membrane of mammalian cells and that its function is modulated by cholesterol (23) . Our observations that the multidrug ABC transporter Cdrlp was poorly localized and that the efflux of the fluorophore R6G was severely hampered in Candida ceUs when interactions between ergosterol and sphingolipids were disrupted suggest similar possibilities. It is thus tempting to speculate that Cdrlp, a homologue of human Pgp, may also preferentially reside within such membrane rafts, a possibility which needs to be examined. In addition, the disruption of interactions between the membrane lipid components probably results in the rnislocalization of Cdrlp, which in tum affects its functioning.
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